We aim at exploring and validating imaging biomarkers for an improved diagnosis and follow-up of patients suffering neurological complaints such as dementia, multiple sclerosis, traumatic brain injury, Parkinson’s disease, and others. The UK Biobank will allow us to create normative data of our developed diagnostic metrics, as well as normative atlases. The comparison to a normative cohort bears thereby a major clinical benefit for the clinicians to make better decisions, which has a direct positive effect on the patients.
